Suppr超能文献

阿片类药物与安慰剂或其他治疗方法治疗慢性腰痛的比较:Cochrane系统评价的更新

Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review.

作者信息

Chaparro Luis Enrique, Furlan Andrea D, Deshpande Amol, Mailis-Gagnon Angela, Atlas Steven, Turk Dennis C

机构信息

*Department of Anesthesiology, Hospital Pablo Tobon Uribe, Medellin, Colombia; †Institute for Work and Health, Toronto, Canada; ‡Toronto Western Hospital, Comprehensive Pain Program, University Health Network, Toronto, Canada; §Department of Medicine, Toronto Western Hospital, Comprehensive Pain Program, Toronto, Canada; ¶Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, MA; and ‖Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.

出版信息

Spine (Phila Pa 1976). 2014 Apr 1;39(7):556-63. doi: 10.1097/BRS.0000000000000249.

Abstract

STUDY DESIGN

Systematic review and meta-analysis.

OBJECTIVE

To assess the efficacy of opioids in adults with chronic low back pain (CLBP).

SUMMARY OF BACKGROUND DATA

Opioids for CLBP has increased dramatically. However, the benefits and risks remain unclear.

METHODS

We updated a 2007 Cochrane Review through October 2012 of randomized controlled trials from multiple databases. Use of noninjectable opioids in CLBP for at least 4 weeks was compared with placebo or other treatments; comparisons with different opioids were excluded. Outcomes included pain and function using standardized mean difference (SMD) or risk ratios with 95% confidence intervals (CIs), and absolute risk difference with 95% CI for adverse effects. Study quality was evaluated using Grading of Recommendations Assessment, Development, and Evaluation criteria.

RESULTS

Fifteen trials (5540 participants), including twelve new, met the criteria. Tramadol was better than placebo for pain (SMD, -0.55; 95% CI, -0.66 to -0.44) and function (SMD, -0.18; 95% CI, -0.29 to -0.07). Compared with placebo, transdermal buprenorphine decreased pain (SMD, -2.47; 95% CI, -2.69 to -2.25), but not function (SMD, -0.14; 95% CI, -0.53 to 0.25). Strong opioids (morphine, hydromorphone, oxycodone, oxymorphone, and tapentadol), were better than placebo for pain (SMD, -0.43; 95% CI, -0.52 to -0.33) and function (SMD, -0.26; 95% CI, -0.37 to -0.15). One trial demonstrated little difference with tramadol compared with celecoxib for pain relief. Two trials (272 participants) found no difference between opioids and antidepressants for pain or function. Reviewed trials had low to moderate quality, high drop-out rates, short duration, and limited interpretability of functional improvement. No serious adverse effects, risks (addiction or overdose), or complications (sleep apnea, opioid-induced hyperalgesia, hypogonadism) were reported.

CONCLUSION

There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo. The effectiveness and safety of long-term opioid therapy for treatment of CLBP remains unproven.

摘要

研究设计

系统评价与荟萃分析。

目的

评估阿片类药物对慢性下腰痛(CLBP)成人患者的疗效。

背景数据总结

用于CLBP的阿片类药物用量已大幅增加。然而,其益处和风险仍不明确。

方法

我们更新了2007年的Cochrane系统评价,纳入截至2012年10月来自多个数据库的随机对照试验。将CLBP患者中使用非注射用阿片类药物至少4周的情况与安慰剂或其他治疗方法进行比较;排除不同阿片类药物之间的比较。结局指标包括采用标准化均数差(SMD)或风险比及95%置信区间(CI)的疼痛和功能指标,以及采用95%CI的不良反应绝对风险差。使用推荐分级的评估、制定与评价标准对研究质量进行评估。

结果

15项试验(5540名参与者)符合标准,其中包括12项新试验。曲马多在疼痛(SMD,-0.55;95%CI,-0.66至-0.44)和功能(SMD,-0.18;95%CI,-0.29至-0.07)方面优于安慰剂。与安慰剂相比,透皮丁丙诺啡可减轻疼痛(SMD,-2.47;95%CI,-2.69至-2.25),但对功能无影响(SMD,-0.14;95%CI,-0.53至0.25)。强效阿片类药物(吗啡、氢吗啡酮、羟考酮、奥施康定和氨酚羟考酮)在疼痛(SMD,-0.43;95%CI,-0.52至-0.33)和功能(SMD,-0.26;95%CI,-0.37至-0.15)方面优于安慰剂。一项试验表明,在疼痛缓解方面,曲马多与塞来昔布相比差异不大。两项试验(272名参与者)发现,阿片类药物与抗抑郁药在疼痛或功能方面无差异。纳入综述的试验质量低至中等,脱落率高,持续时间短,功能改善的可解释性有限。未报告严重不良反应、风险(成瘾或过量)或并发症(睡眠呼吸暂停、阿片类药物诱导的痛觉过敏、性腺功能减退)。

结论

与安慰剂相比,有证据表明阿片类药物治疗CLBP具有短期疗效(疼痛方面为中度,功能方面为轻度)。长期阿片类药物治疗CLBP的有效性和安全性仍未得到证实。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验